drugset / Trial / NCT00263354

Oxaliplatin in Gastric Cancer

NCT00263354 ↗

Phase 2 Completed 20 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the objective response to oxaliplatin/5FU/leucovorin combination chemotherapy in patients with advanced unresectable or metastatic gastric cancer.

Timeline

Start
2003-10
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule — —

Indications